Ozempic NAION Warning: FDA Adds Rare Eye Risk to Every GLP-1 Drug Label
The FDA now requires all 12 GLP-1 drugs, including Ozempic, Wegovy and Mounjaro, to warn of NAION, a rare cause of sudden vision loss. Here…
The FDA now requires all 12 GLP-1 drugs, including Ozempic, Wegovy and Mounjaro, to warn of NAION, a rare cause of sudden vision loss. Here…
A CDSCO expert panel recommended a Phase I trial of Indian Immunologicals' live attenuated Zika vaccine, developed with Griffith University and funded by ICMR.
PMV Pharmaceuticals' rezatapopt produced a 48% response rate in platinum-resistant ovarian cancer with TP53 Y220C in the pivotal PYNNACLE trial, with an FDA filing planned…
Mayo Clinic data from ObesityWeek 2026 show GLP-1 users with weakened hearts saw greater one-year gains in heart structure and function than matched non-users, with…
Up to 15 people have died and more than 300 have sought care in Imphal after drinking spurious liquor in Manipur's Chandel district. What we…
The FDA now requires all 12 GLP-1 drugs, including Ozempic, Wegovy and Mounjaro, to warn…
The FDA now requires all 12 GLP-1 drugs, including Ozempic, Wegovy and Mounjaro, to warn of NAION, a rare cause of sudden vision loss. Here is what the data show.
A CDSCO expert panel recommended a Phase I trial of Indian Immunologicals' live attenuated Zika vaccine, developed with Griffith University and funded by ICMR.
PMV Pharmaceuticals' rezatapopt produced a 48% response rate in platinum-resistant ovarian cancer with TP53 Y220C in the pivotal PYNNACLE trial, with an FDA filing planned for Q1 2027.
Mayo Clinic data from ObesityWeek 2026 show GLP-1 users with weakened hearts saw greater one-year gains in heart structure and function than matched non-users, with most benefits holding after adjusting…
Up to 15 people have died and more than 300 have sought care in Imphal after drinking spurious liquor in Manipur's Chandel district. What we know, and how methanol poisoning…
Updated RMC-GI-102 data at ENA 2026 show Rasonque (daraxonrasib) plus gemcitabine and nab-paclitaxel achieved a 60.7% response rate, 12.8-month PFS and 76.6% one-year survival in untreated metastatic pancreatic cancer.
Innogen has licensed its China-approved GLP-1 efsubaglutide alfa to Arcera for Africa, Eastern Europe, Latin America and the Middle East in a deal worth over $1 billion.
FDA approves once-weekly Sogroya for growth failure in Turner syndrome. REAL8 data, side effects, limits and what it means for families.
Erasca's oral pan-RAS molecular glue ERAS-0015 produced a 44% confirmed response rate in pretreated KRAS-mutant pancreatic cancer, 69% in G12D/G12V tumours, in Phase 1.
A Science review weighs whether Ozempic, Wegovy and Mounjaro protect the brain. Observational data look promising, but Alzheimer trials were negative. What we know.